Hanmi Pharmaceutical achieved a record high in sales last year. Hanmi Pharmaceutical said on the 5th that it posted consolidation sales of 1.5475 trillion won last year. That was up 3.5% from a year earlier. Operating profit rose 19.2% to 257.8 billion won. Net profit was 188.1 billion won. It increased 33.9% from a year earlier.
According to Hanmi Pharmaceutical, last year's operating margin was 16.7%, among the highest in the industry. Hanmi Pharmaceutical invested 229 billion won in research and development last year. That amounts to 14.8% of total sales.
Hanmi Pharmaceutical logged 1.0836 trillion won in sales from outpatient prescriptions (prescriptions to buy medicine outside hospitals) last year. The company said it ranked No. 1 in Korea for outpatient prescription sales for eight consecutive years. The dyslipidemia combination new drug Rosuzet recorded 227.9 billion won in prescription sales. The AmozeTan Family, a portfolio of combination drugs for hypertension treatment, posted 145.4 billion won in sales.
Beijing Hanmi Pharmaceutical, the local subsidiary in China, recorded cumulative sales of 402.4 billion won last year. Operating profit was 77.7 billion won, and net profit was 67.4 billion won. It is the first time since its founding in 1996 that Beijing Hanmi Pharmaceutical has surpassed 400 billion won in sales. Respiratory disease medicines sold more as distribution inventories were cleared in China and the seasonal peak took effect. In addition, Hanmi Fine Chemical, an active pharmaceutical ingredient affiliate, posted 91.3 billion won in sales last year.
Hanmi Pharmaceutical said its "H.O.P (Hanmi Obesity Pipeline)" project is proceeding smoothly. H.O.P is Hanmi Pharmaceutical's obesity treatment project that sequentially introduces various customized therapies in line with the obesity treatment cycle.
The obesity drug candidate Efecleinatide is set to be commercialized in the second half of this year. Efpeglenatide is being developed as a customized obesity treatment reflecting the body shape and weight of Koreans. The triple agonist HM15275 is targeting commercialization in 2030. HM17321, an obesity treatment that reduces fat and increases muscle mass, is moving its clinical development forward ahead of commercialization in 2031.
Hanmi Pharmaceutical plans to sequentially announce key pipeline (new drug candidate) clinical results in oncology, metabolism, and rare diseases at overseas conferences this year. A Hanmi Pharmaceutical official said, "After the management rights dispute ended, we stabilized operations under a professional management system and posted record results." Hanmi Pharmaceutical CEO Park Jae-hyun said, "We will focus companywide capabilities to create sustainable performance and raise corporate value."